UPDATE: Disclosure Insight Downgrades Alexion Pharmaceuticals to Medium Risk - Negative Bias

Disclosure Insight lowers its rating on Alexion Pharmaceuticals

to reflect ongoing litigation related to the manufacture of Soliris. Disclosure Insight notes, "Concentrated revenue and ongoing litigation support our opinion of a Medium Risk - Negative Bias rating on ALXN. The company is involved in a lawsuit filed by Novartis alleging that the manufacture of Soliris infringes on one of its patents. The matter appeared ongoing as of the 10-Q filed 31-Oct-11. Soliris has accounted for “essentially all” of the ALXN's revenue since its launch in Apr-07." ALXN closed at $67.54 per share on Wednesday.